Free Trial

$8.75B GlaxoSmithKline (GSK), 7Pt Launched


GSK 7Pt leads with $8.75B multi-tranche jumbo. Still waiting for Philippines Bank and KEB Hana Bank to launch.

  • Date $MM Issuer (Priced *, Launch #)
  • 03/21 $8.75B #GlaxoSmithKline (GSK) $700M 2NC1 +90, $300M 2NC1 SOFR+89, $1.75B 3Y +90, $2B 5Y +110, $1B 7Y +115, $2B 10Y +135, $1B 30Y +158
  • 03/21 $4B #ING $1.25B 4NC3 +155, $500M 4NC3 SOFR+164, $1.25B 6NC5 +170, $1B 11NC10 +195
  • 03/21 $750M #Humana 7Y +137.5
  • 03/21 $525M #Union Electric 30Y +135
  • 03/21 $1.25B #Sempra $750M 3Y +102, $500M 7Y +140
  • 03/21 $Benchmark Philippines Bank 5Y +125a, 10.5Y +165a, 25Y 4.7%a
  • 03/21 $Benchmark KEB Hana Bank 3Y, 5Y investor calls
  • Rolled to Tuesday:
  • 03/22 $1B IBRD (World Bank) 2Y +17a, 10Y +41a
  • 03/22 $Benchmark Kommunalbanken 2.5Y SOFR+27a

To read the full story



MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.